GSK PLC (GS71.DE) Stock Price & Overview
FRA:GS71 • GB00BN7SWP63
Current stock price
The current stock price of GS71.DE is 24.96 EUR. Today GS71.DE is up by 0.44%. In the past month the price increased by 4.44%. In the past year, price increased by 66.46%.
GS71.DE Key Statistics
- Market Cap
- 101.331B
- P/E
- 12.67
- Fwd P/E
- 11.69
- EPS (TTM)
- 1.97
- Dividend Yield
- 3.23%
GS71.DE Stock Performance
GS71.DE Stock Chart
GS71.DE Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to GS71.DE. When comparing the yearly performance of all stocks, GS71.DE is one of the better performing stocks in the market, outperforming 91.45% of all stocks.
GS71.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to GS71.DE. GS71.DE has an excellent profitability rating, but there are concerns on its financial health.
GS71.DE Earnings
On February 4, 2026 GS71.DE reported an EPS of 0.26 and a revenue of 8.62B. The company beat EPS expectations (8.69% surprise) and missed revenue expectations (-1.24% surprise).
GS71.DE Forecast & Estimates
32 analysts have analysed GS71.DE and the average price target is 23.92 EUR. This implies a price decrease of -4.15% is expected in the next year compared to the current price of 24.96.
For the next year, analysts expect an EPS growth of 8.2% and a revenue growth 4.1% for GS71.DE
GS71.DE Groups
Sector & Classification
GS71.DE Financial Highlights
Over the last trailing twelve months GS71.DE reported a non-GAAP Earnings per Share(EPS) of 1.97. The EPS increased by 7.84% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 17.5% | ||
| ROA | 9.35% | ||
| ROE | 34.9% | ||
| Debt/Equity | 0.9 |
GS71.DE Ownership
GS71.DE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1SAN | SANOFI | 9.4 | 97.617B | ||
| SAN | SANOFI | 9.27 | 97.205B | ||
| SNW | SANOFI | 9.36 | 97.193B | ||
| UCB | UCB SA | 25.95 | 53.49B | ||
| UNC | UCB SA | 25.91 | 53.218B | ||
| MRK | MERCK KGAA | 14.33 | 48.63B | ||
| 1MRK | MERCK KGAA | 13.62 | 46.695B | ||
| 1BAYN | BAYER AG-REG | 9.21 | 39.808B | ||
| BAYN | BAYER AG-REG | 9.27 | 39.415B | ||
| IPN | IPSEN | 13.15 | 14.315B | ||
| REC | RECORDATI INDUSTRIA CHIMICA | 16.37 | 10.214B | ||
| TUB | FINANCIERE DE TUBIZE | N/A | 10.059B | ||
| VIRP | VIRBAC SA | 16.81 | 3.02B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About GS71.DE
Company Profile
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. The company develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.
Company Info
IPO: 1972-05-22
GSK PLC
980 Great West Road
Brentford MIDDLESEX GB
Employees: 66841
Phone: 442080475000
GSK PLC / GS71.DE FAQ
Can you describe the business of GSK PLC?
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. The company develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.
What is the current price of GS71 stock?
The current stock price of GS71.DE is 24.96 EUR. The price increased by 0.44% in the last trading session.
Does GS71 stock pay dividends?
GSK PLC (GS71.DE) has a dividend yield of 3.23%. The yearly dividend amount is currently 0.72.
How is the ChartMill rating for GSK PLC?
GS71.DE has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What do analysts say about GSK PLC (GS71.DE) stock?
32 analysts have analysed GS71.DE and the average price target is 23.92 EUR. This implies a price decrease of -4.15% is expected in the next year compared to the current price of 24.96.
How is the valuation of GSK PLC (GS71.DE) based on its PE ratio?
The PE ratio for GSK PLC (GS71.DE) is 12.67. This is based on the reported non-GAAP earnings per share of 1.97 and the current share price of 24.96 EUR.
Is GSK PLC (GS71.DE) expected to grow?
The Revenue of GSK PLC (GS71.DE) is expected to grow by 4.1% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.